Market capitalization | $8.42b |
Enterprise Value | $8.31b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 23.07 |
P/S ratio (TTM) P/S ratio | 23.36 |
P/B ratio (TTM) P/B ratio | 12.58 |
Revenue growth (TTM) Revenue growth | 18.70% |
Revenue (TTM) Revenue | $360.35m |
As a Free StocksGuide user, you can view scores for all 6,885 stocks worldwide.
16 Analysts have issued a Glaukos Corp forecast:
16 Analysts have issued a Glaukos Corp forecast:
Sep '24 |
+/-
%
|
||
Revenue | 360 360 |
19%
19%
|
|
Gross Profit | 282 282 |
20%
20%
|
|
EBITDA | -73 -73 |
5%
5%
|
EBIT (Operating Income) EBIT | -110 -110 |
4%
4%
|
Net Profit | -150 -150 |
16%
16%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in San Clemente, CA.
Head office | United States |
CEO | Thomas Burns |
Employees | 907 |
Founded | 1998 |
Website | www.glaukos.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.